Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.